引用 | PubMed報導
Peptide-based therapies for arthritis
Abstract 迄今為止，用於關節炎的治療藥物主要包括使用與鎮痛、減少炎症或疾病改變有關的小分子。這些小分子易於製造、穩定並且可以以相對較低的每單位生產成本生產。隨著生物技術的進步，過去二十年中單克隆抗體 (mAb) 的應用不斷增加，並且越來越多的具有特定靶點的新療法可用於治療自身免疫性疾病。單克隆抗體在治療類風濕性關節炎 (RA) 中的應用引領了這些化合物在醫學上的臨床應用 他們現在在這些患者的管理中發揮著核心作用。目前，市場上或臨床試驗中的生物製劑數量越來越多，不僅用於治療關節炎（表 1），而且還用於更廣泛的醫學疾病。隨著對疾病病理生理學認識的增加，加上大規模低成本合成新化合物的能力，方法發生了變化，更新的治療策略正在將我們帶入治療的新時代。總的來說，傳統小分子來源於天然產物（例如植物和樹皮）並在多個測定係統中測試其功效的日子已經一去不復返了。 To date, therapeutic drugs used in arthritis have largely consisted of the use of small molecules involved with analgesia, reducing inflammation or disease modification. These small molecules are easy to manufacture, are stable and can be produced at a relatively low cost per unit of production. With advances in biotechnology the use of monoclonal antibodies (mAbs) over the last two decades has grown in application and newer therapies with specific targets are becoming increasingly available for the treatment of autoimmune diseases. The use of mAbs in the treatment of rheumatoid arthritis (RA) has led the way in medicine for the clinical application of these compounds  and they now occupy a central role in the management of these patients. Currently, there is a large and growing number of biologic agents on the market or in clinical trials not only for arthritis (Table 1), but for use in a wider range of medical diseases. With the increase in understanding of the pathophysiology of diseases, combined with the ability to synthesize new compounds on a large scale with low costs, there has been a change in approach and newer therapeutic strategies are leading us into a new era of therapeutics. By and large, gone are the days where the traditional small molecules were derived from natural products (e.g., plants and tree bark) and tested in multiple assay systems for efficacy. The new era of drug design, based on better understanding of disease processes, molecular recognition of cellular and protein events and the ability to disrupt such crucial interactions, has come of age.